{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2120337"],"location":["France"],"study_start_month":["7"],"keyword":["Raltitrexed","Oxaliplatin","Unresectable metastases","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"2nd-line Treatment of Metastatic Colorectal Cancer","description":"This phase 2 trial aims to evaluate the continued use of bevacizumab with raltitrexed and oxaliplatin combination versus FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer whose disease has progressed after irinotecan-based chemotherapy.","dates":{"creation":"2011-07-15"},"accession":"2120337","cross_references":{"ClinicalTrials___gov":["NCT01532804"],"EU Clinical Trials Register":["2010-023447-15"]}}